Mirvetuximab soravtansine-gynx is approved by the USFDA for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
Mirvetuximab soravtansine-gynx is approved by the USFDA for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer